Notice of Appeal
Single technology appraisal
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651]
NICE has received three appeals, that fall within one or more of the two strictly limited grounds for appeal, against the Final Draft Guidance on the above technology from the following organisations:
- UCB Pharma Limited
- Tuberous Sclerosis Association
- Royal College of Physicians
British Paediatric Neurology Association submitted an appeal letter, but their appeal was rejected during the scrutiny stage.
The appeal panel will convene on 6 September 2024 at 9:00am via Zoom to hear oral representations from the appellants
Members of the public, including consultees and commentators for this appraisal, and the press, may request to attend the hearing.
Where possible, requests to attend should be made using the registration link that will be available on our website from Monday 10 June 2024. The registration for this appeal will end at 4:00pm on Friday 30 August 2024.
Further details relating to public attendance at this appeal are available on the same webpage as above.